Charles River Laboratories International (CRL) EBT (2009 - 2026)

Charles River Laboratories International has reported EBT for 18 years, with the latest figure at $53.2 million in Q2 2026.

• On a quarterly basis, EBT fell 25.55% year-over-year to $53.2 million in Q2 2026; TTM through Jun 2026 was -$183.7 million, a 911.74% decrease from a year earlier, with the FY2025 full-year figure at -$99.5 million, down 206.86% from the prior year.
• EBT was $53.2 million for Q2 2026 at Charles River Laboratories International, up from -$29.9 million in the prior quarter.
• The five-year high for EBT was $244.9 million in Q4 2022, with the low at -$294.1 million in Q4 2025.
• Average EBT over 5 years is $67.8 million, with a median of $104.9 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: EBT jumped 67.18% in 2022, then tumbled 203.87% in 2024.
• Over 5 years, EBT stood at $244.9 million in 2022, then fell by 14.79% to $208.7 million in 2023, then sank by 203.87% to -$216.8 million in 2024, then slumped by 35.66% to -$294.1 million in 2025, then surged by 118.08% to $53.2 million in 2026.
• The last three EBT figures came in at $53.2 million (Q2 2026), -$29.9 million (Q1 2026), and -$294.1 million (Q4 2025), per Business Quant data.